mg - I think that is too high, Pascoe and Matt Beck have said that peak Vitaros sales Ex-US are estimated to be about $50M per year and USA peak sales would be about $150M per year. Not sure if they meant once the RTD came out. Rayva is not worth top dollar unless approved, can't get as much for a PH2 product, a buyer would have to take the risk of PH3.
I agree with old coach, maybe Vitaros is worth $10 and Rayva maybe a couple bucks at a 10M share count float.
News 
Market Data 
Discover 
